News

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...
The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...
Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...
Foster City-headquartered Gilead Sciences Inc, a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the US FDA has approved ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the U.S. Food and Drug Administration has approved Yeztugo (lenacapavir)-the company's injectable HIV-1 capsid inhibitor-as pre-exposure ...
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval More than 100 people in the US were diagnosed with HIV every day in 2023 Gilead Sciences’ twice-yearly injectable pre-exposure ...
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.
The FDA has approved Gilead Sciences’ Yeztugo (lenacapavir) as the first and only twice-yearly injectable option for HIV pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 77 ...
HIV Drug: The U.S. FDA has approved Gilead Sciences' Yeztugo, a twice-yearly injection for HIV prevention, aiming to change the landscape of HIV care. This revolutionary treatment costs $28,218 ...